ESPR CFO Sells 7,229 Shares at $1.15 for Tax Withholding – Form 4

Esperion Therapeutics (ESPR) – Form 4 insider filing: Chief Financial Officer Benjamin Halladay reported the sale of 7,229 common shares on 06/17/2025 at $1.152 per share, generating roughly $8,300 in proceeds.

Rhea-AI Filing Summary

Esperion Therapeutics (ESPR) – Form 4 insider filing: Chief Financial Officer Benjamin Halladay reported the sale of 7,229 common shares on 06/17/2025 at $1.152 per share, generating roughly $8,300 in proceeds. The company states the disposition was made solely to cover withholding taxes on recently-vested RSUs. Following the transaction, Halladay still directly holds 474,473 ESPR shares. No derivative transactions or additional dispositions were disclosed, and the filing indicates the sale was effected under a routine tax-settlement, not a 10b5-1 trading plan.

Insights

Financial Analyst

TL;DR: Minor tax-related sale; neutral signal.

The CFO’s sale represents <2% of his beneficial ownership and an immaterial fraction of Esperion’s ~106 million outstanding shares. Because the purpose was tax withholding on vested RSUs, the sale does not suggest a change in insider sentiment. With the executive still holding nearly half a million shares, alignment with shareholders remains intact. Given the low dollar value (<$10k) and absence of strategic context, the filing is operationally insignificant for valuation models and should not materially impact the stock price.

Insider Trade Summary

Net Seller: 7,229 shares

Net Sell 1 txn

Insider Halladay Benjamin

Role Chief Financial Officer

Sold 7,229 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,229	$1.152	$8K

Holdings After Transaction: Common Stock — 474,473 shares (Direct)

Footnotes (1)

1. F1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Esperion (ESPR) shares did the CFO sell in the Form 4?

7,229 common shares were sold.

At what price were the ESPR shares sold?

The shares were sold at $1.152 per share.

Why did Benjamin Halladay sell ESPR shares?

The sale was conducted to cover payroll taxes on vested RSUs.

How many ESPR shares does the CFO still own after the sale?

He retains 474,473 shares directly.

Was the transaction made under a Rule 10b5-1 trading plan?

The filing does not indicate use of a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2025 - 06:44 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Halladay Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		S		7,229(1)	D	$1.152	474,473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.